Bain Capital Life Sciences
Bain Capital Life Sciences Fund specializes in buyouts, inflection capital, growth capital, turnaround, and private equity investments.
Business Model:
Revenue: $0
Employees: 11-50
Rankings
Industries / Tags:
Detailed Bain Capital Life Sciences Information
Geographic Data
Address: 200 Clarendon Street
City: Boston
State: MA
Zip: 02116
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Metrics
5,211,694Website Global Rank
1,756Website Monthly Traffic
Twitter Followers
Description
Bain Capital Life Sciences Fund specializes in buyouts, inflection capital, growth capital, turnaround, and private equity investments.
Contact Phone:
+16175162000
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2020 | C4 Therapeutics | Series B | 150M |
| 9/2019 | Pharvaris | Series B | 66M |
| 7/2021 | Imperative Care | Series D | 0 |
| 1/2020 | Kestra Medical Technologies, Inc. | Private Equity Round | - |
| 5/2020 | Rapid Micro Biosystems | Private Equity Round | 0 |
| 1/2020 | Savara Pharmaceuticals | Post-IPO Equity | 26.8M |
| 11/2022 | Emalex Biosciences | Series D | 250M |
| 12/2019 | Imperative Care | Series C | 0 |
| 1/2021 | EQRx | Series B | 500M |
| 2/2020 | JenaValve Technology | Series D | 0 |
| 12/2019 | Marinus Pharmaceuticals | Post-IPO Equity | 70M |
| 4/2017 | Hugel Control | Post-IPO Equity | 816M |
| 4/2002 | Dynavax Technologies | Series D | 0 |
| 12/2017 | Aptinyx | Series B | 70M |
| 3/2021 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
| 5/2018 | Rapid Micro Biosystems | Private Equity Round | 60M |
| 1/2021 | River 2 Renal | Series A | 40M |
| 9/2017 | Marinus Pharmaceuticals | Post-IPO Equity | 40.3M |
| 9/2017 | Replimune Group | Series B | 55M |
| 3/2020 | Nurix Therapeutics | Private Equity Round | 120M |
| 2/2021 | Xilio Therapeutics | Series C | 95M |
| 11/2020 | Pharvaris | Series C | 80M |
| 9/2018 | Arcutis Biotherapeutics | Series B | 58M |
| 11/2022 | New Amsterdam Pharma | Post-IPO Equity | 0 |
| 11/2018 | ViaCyte | Series D | 0 |
| 12/2020 | Syros Pharmaceuticals | Post-IPO Equity | 90.5M |
| 1/2018 | Gynesonics | Private Equity Round | 75M |
| 8/2020 | Freenome | Series C | 270M |
| 4/2023 | HeartFlow | Series F | 0 |
| 3/2022 | 2seventy bio | Post-IPO Equity | 0 |
| 4/2020 | Mersana Therapeutics | Post-IPO Equity | 0 |
| 2/2020 | JenaValve Technology | Venture Round | 50M |
| 4/2021 | Crinetics Pharmaceuticals | Post-IPO Equity | 75M |
| 12/2021 | Freenome | Series D | 300M |
| 4/2020 | Affinivax | Series B | 120M |
| 9/2022 | Nimbus Therapeutics | Venture Round | 0 |
| 6/2021 | Nautilus Biotechnology | Post-IPO Equity | 0 |
| 3/2017 | Dicerna Pharmaceuticals | Post-IPO Debt | 0 |
| 6/2022 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
| 10/2018 | Cerevel Therapeutics | Private Equity Round | 0 |
| 1/2020 | EQRx | Series A | 200M |
| 10/2020 | AavantiBio | Series A | 0 |
| 5/2020 | Atea | Series D | 215M |
| 12/2018 | Annexon Biosciences | Series C | 75M |
| 8/2022 | JenaValve Technology | Series C | 0 |
| 8/2021 | Tango Therapeutics | Post-IPO Equity | 0 |
| 9/2022 | Solid Biosciences | Post-IPO Equity | 75M |
| 9/2022 | Rivus Pharmaceuticals | Series B | 132M |
| 3/2017 | Solid Biosciences | Series C | 0 |
| 10/2019 | Constellation Pharmaceuticals | Post-IPO Equity | 65M |
| 6/2023 | Upstream Bio | Series B | 0 |
| 9/2017 | SpringWorks Therapeutics | Series A | 103M |
| 7/2020 | Thrive Earlier Detection | Series B | 0 |
| 11/2022 | Jnana Therapeutics | Series C | 0 |
| 10/2017 | InflaRx | Series D | 55M |
| 3/2020 | Kymera Therapeutics | Series C | 102M |
| 5/2021 | Nuvalent | Series B | 0 |
| 7/2021 | Amylyx Pharmaceuticals | Series C | 0 |
| 1/2021 | River 3 Renal | Series A | 40M |
| 12/2020 | Solid Biosciences | Post-IPO Equity | 0 |
| 7/2022 | Areteia Therapeutics | Series A | 0 |
| 7/2022 | Annexon Biosciences | Post-IPO Equity | 0 |
| 3/2021 | Amunix | Series B | 117M |
| 12/2021 | EQRx | Post-IPO Equity | 0 |
| 5/2021 | Interius BioTherapeutics | Series A | 0 |
| 3/2020 | ViaCyte | Series D | 0 |
| 7/2022 | Areteia Therapeutics | Series A | 0 |
| 7/2022 | Annexon Biosciences | Post-IPO Equity | 0 |
| 6/2022 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
| 3/2022 | 2seventy bio | Post-IPO Equity | 0 |
| 12/2021 | EQRx | Post-IPO Equity | 0 |
| 12/2021 | Freenome | Series D | 0 |
| 8/2021 | Tango Therapeutics | Post-IPO Equity | 0 |
| 7/2021 | Amylyx Pharmaceuticals | Series C | 0 |
| 7/2021 | Imperative Care | Series D | 0 |
| 6/2021 | Nautilus Biotechnology | Post-IPO Equity | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
